Amphetamine Stimulant Prodrug denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for amphetamine stimulant prodrug are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Issued a Not-FDA-Approved Denial

Humana may issue a "not FDA-approved" denial for an amphetamine-based stimulant prodrug when the specific formulation, strength, or indication on the prescription does not map cleanly to an FDA-approved use in Humana's claims or clinical-review system. These denials can also result from diagnosis-code mismatches, where the condition listed on the claim does not correspond to a labeled indication — even if the drug itself is FDA-approved for other indications. The denial may be a system error rather than a correct clinical finding.

## Why This Denial Is Frequently Overturned

If the drug genuinely holds FDA approval for the diagnosed condition, the denial rests on a factual error that a well-documented appeal can correct. The FDA approval record is publicly verifiable. Under ACA §2719 and ERISA §503, you have the right to a full internal appeal and independent external review. The external-review window is generally available for approximately four months after a final internal denial. An expedited review option is available when urgent circumstances apply.

## Appeal Process and Timeline

1. Obtain the denial letter specifying the exact basis — which indication or formulation was deemed unapproved, and which clinical policy was applied. 2. Verify FDA approval on DailyMed (dailymed.nlm.nih.gov) for the drug and indication on the prescription. 3. File the internal appeal within Humana's deadline (typically 60 days from denial). Humana must respond within 30 days (pre-service) or 60 days (post-service). 4. If denied internally, request independent external review through Humana or your state insurance commissioner. External reviewers apply objective FDA-approval standards, not just Humana's internal policy.

## Documentation to Gather

• FDA label from DailyMed: Print the current approved labeling showing the indications section. Highlight the indication that matches the patient's diagnosis.
• Diagnosis confirmation: Office notes with a documented diagnosis corresponding to an FDA-approved indication for this drug.
• Prescriber medical-necessity letter: States the diagnosis, identifies the FDA-approved indication being utilized, and explains the clinical rationale for this specific drug.
• Claim coding review: Ask the prescriber's billing staff to verify that the diagnosis code submitted matches the FDA-approved indication — a coding correction may resolve the denial without a full appeal.
• Humana's coverage policy: Obtain the current policy for this drug class to understand the exact criteria Humana is applying.

## Criteria-Mapping Structure

Build a table with Humana's coverage criteria in the left column and the corresponding evidence in the right. For a not-FDA-approved denial specifically, the most important exhibit is the FDA label page showing the approved indication alongside the medical record confirming the patient's diagnosis matches that indication. When these two documents align, the factual premise of the denial is directly contradicted.